Redwood AI Partners with UBC to Develop Novel Alzheimer's Therapeutics Targeting NUDT5 Protein
Key Insights
Redwood AI Corp. (search) has launched a collaborative research project with the University of British Columbia's Brent Page Lab (search) to develop novel drugs for Alzheimer's disease (search) targeting the NUDT5 (search) protein.
The initiative combines Redwood's AI-driven computational platform with the Page Lab's medicinal chemistry expertise to design and optimize inhibitors for neurodegeneration (search)-associated biological stress signaling.
The project aims to accelerate early-stage drug discovery by generating virtual compound libraries and identifying novel candidates with promising safety and efficacy profiles.
Redwood AI Corp. (search) has announced a collaborative research initiative with the University of British Columbia's Brent Page Lab (search) to advance the development of novel therapeutics for Alzheimer's disease (search). The project, titled "Novel Therapeutics for Neurodegeneration (search) - Targeting NUDT5 (search) in Alzheimer's Disease," represents a strategic partnership combining artificial intelligence-driven drug discovery with academic medicinal chemistry expertise.
Addressing Critical Global Health Need
The collaboration comes at a time when dementia (search) represents one of the most pressing global health challenges. With more than 55 million people worldwide living with dementia, including over 750,000 Canadians, and a new case arising somewhere in the world every 3 seconds, the initiative targets one of the most urgent and fast-growing unmet medical needs in global health.
NUDT5 as Therapeutic Target
The research will focus specifically on designing and optimizing inhibitors targeting NUDT5 (search), a protein involved in biological stress-related signaling processes associated with neurodegeneration (search) in Alzheimer's disease (search). This protein target represents a novel approach to addressing the underlying mechanisms of neurodegeneration.
Redwood will deploy its computational platform to generate and evaluate virtual libraries of synthetically tractable analogue compounds. The goal is to guide compound selection and accelerate the experimental work being conducted by the Page Lab, potentially identifying novel compound candidates with promising in-silico safety and efficacy profiles.
AI-Enhanced Drug Discovery Approach
The collaboration leverages Redwood's AI-driven computational drug research platform to identify molecules that may not have been readily identified through traditional medicinal chemistry approaches. These computationally-designed candidates could then be rapidly prioritized for synthesis and testing, potentially accelerating early discovery timelines.
"We believe AI will play an increasingly central role in how new medicines are discovered and developed over the next decade," said Louis Dron, CEO of Redwood AI. "By pairing advanced computational design with world class academic science, we aim to help shorten the path from early discovery to stronger preclinical candidates."
Validation and Translation Challenges
The project addresses a critical challenge in drug discovery where many theoretically promising compounds fail to demonstrate efficacy in practice. The Page Lab will conduct experimental validation to confirm whether computational predictions translate into real-world biological activity, representing a key step in the drug development process.
By combining artificial intelligence with medicinal chemistry and biological testing, the project is intended to improve the efficiency of promising candidates for early-stage drug discovery and help advance them toward future preclinical development.
Research Partnership Details
The Brent Page Lab (search) brings expertise in chemical probe design and medicinal chemistry, with a particular focus on structure-based drug discovery and experimental testing. Their work involves identifying how small molecules interact with protein targets using molecular docking, chemical synthesis, and advanced biochemical assays.
Dron emphasized the broader potential of this collaborative model, stating that "programs like this one are building a foundation for a faster, more efficient approach to therapeutic innovation, and we see significant long term potential for this model across multiple disease areas."